Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 20/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1356215 | 0.92 | HTR6 (0.55) | HTR6CYP3A4CYP2D6POLBL3MBTL1 | |
| Hydrochloric Acid SCHEMBL1356650 | 0.89 | HTR6 (0.72) | HTR6CYP3A4CYP2D6HTR2APOLB | |
| Hydrochloric Acid SCHEMBL1356984 | 0.88 | HTR6 (0.58) | HTR6CYP3A4CYP2D6HTR2APOLB | |
| Hydrochloric Acid SCHEMBL1357568 | 0.87 | HTR6 (0.61) | HTR6 | |
| Hydrochloric Acid SCHEMBL1356472 | 0.85 | HTR6 (0.66) | HTR6CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL1357400 | 0.84 | HTR6 (0.77) | HTR6CYP3A4CYP2D6 | |
| SCHEMBL1356742 | 0.82 | HTR6 (0.69) | HTR6POLBL3MBTL1 | |
| Hydrochloric Acid SCHEMBL1356450 | 0.82 | HTR6 (0.69) | HTR6CYP3A4CYP2D6HTR2AADRA2A | |
| SCHEMBL3200826 | 0.81 | HTR6 (0.77) | HTR6CYP3A4CYP2D6POLBL3MBTL1 | |
| Hydrochloric Acid SCHEMBL1356932 | 0.81 | HTR6 (0.61) | HTR6CYP3A4CYP2D6POLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318725-B2 | Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2012-11-27 | — | — | US | claimed |
| US-20110281849-A1 | Aryl Indolyl Sulfonamide Compounds and Their Use as 5-HT6 Ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2011-11-17 | — | — | US | claimed |
| US-8318725-B2 | Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2012-11-27 | — | — | US | disclosed |
| US-20110281849-A1 | Aryl Indolyl Sulfonamide Compounds and Their Use as 5-HT6 Ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281849-A1 | Aryl Indolyl Sulfonamide Compounds and Their Use as 5-HT6 Ligands | HTR6, HTR1A, HTR2C | HTR6 1/4885CYP3A4 137/4885CYP2D6 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.